Patient characteristics (N = 410)
| . | All cases . | Low-HSF1-pSer326 . | Middle- HSF1-pSer326 . | High- HSF1-pSer326 . | P . |
|---|---|---|---|---|---|
| Total | 100% | 31.7% | 34.9% | 33.4% | |
| Age | |||||
| <1 y | 12.2% | 13.9% | 14.0% | 8.8% | .32 |
| 2-10 y | 33.4% | 36.2% | 28.0% | 36.5% | .23 |
| >11 y | 54.4% | 50.0% | 58.0% | 54.7% | .41 |
| Female sex | 49.0% | 52.3% | 49.7% | 45.3% | .51 |
| Race* | |||||
| American Indian or Alaska Native | 1.1% | 0.9% | 2.3% | 0% | .20 |
| Asian | 4.7% | 4.3% | 4.7% | 5.0% | .96 |
| Black | 11.8% | 6.8% | 13.2% | 15.1% | .12 |
| White | 82.2% | 88.0% | 79.8% | 79.0% | .13 |
| Multiple races | 0.3% | 0% | 0% | 0.8% | .35 |
| Ethnicity† | |||||
| Hispanic | 17.1% | 13.6% | 19.0% | 18.5% | .45 |
| Not Hispanic | 82.9% | 86.4% | 81.0% | 81.5% | |
| Cytogenetics | |||||
| t(8;21) | 15.9% | 10.0% | 14.0% | 23.4% | .01 |
| inv(16) | 13.9% | 16.2% | 16.8% | 8.8% | .10 |
| Normal karyotype | 27.8% | 33.8% | 22.4% | 27.7% | .11 |
| t(9;11)(p22;q23)/11q23 | 17.6% | 15.4% | 17.5% | 19.7% | .65 |
| −5, −7, or +8 | 7.8% | 9.2% | 7.0% | 7.3% | .76 |
| Other | 17.1% | 15.4% | 22.4% | 13.1% | .10 |
| NPM1, mutant | 11.2% | 10.0% | 11.9% | 11.7% | .87 |
| CEBPα, mutant | 9.5% | 16.2% | 7.0% | 5.8% | .01 |
| FLT3-ITD, mutant | 22.4% | 20.8% | 19.6% | 27.0% | .28 |
| High allelic ratio FTL3-ITD (≥ 0.4), yes | 14.6% | 13.1% | 14.0% | 16.8% | .67 |
| Risk stratification, high‡ | 29.8% | 31.0% | 25.9% | 32.6% | .45 |
| CR | 84.9% | 86.2% | 82.5% | 86.1% | .62 |
| . | All cases . | Low-HSF1-pSer326 . | Middle- HSF1-pSer326 . | High- HSF1-pSer326 . | P . |
|---|---|---|---|---|---|
| Total | 100% | 31.7% | 34.9% | 33.4% | |
| Age | |||||
| <1 y | 12.2% | 13.9% | 14.0% | 8.8% | .32 |
| 2-10 y | 33.4% | 36.2% | 28.0% | 36.5% | .23 |
| >11 y | 54.4% | 50.0% | 58.0% | 54.7% | .41 |
| Female sex | 49.0% | 52.3% | 49.7% | 45.3% | .51 |
| Race* | |||||
| American Indian or Alaska Native | 1.1% | 0.9% | 2.3% | 0% | .20 |
| Asian | 4.7% | 4.3% | 4.7% | 5.0% | .96 |
| Black | 11.8% | 6.8% | 13.2% | 15.1% | .12 |
| White | 82.2% | 88.0% | 79.8% | 79.0% | .13 |
| Multiple races | 0.3% | 0% | 0% | 0.8% | .35 |
| Ethnicity† | |||||
| Hispanic | 17.1% | 13.6% | 19.0% | 18.5% | .45 |
| Not Hispanic | 82.9% | 86.4% | 81.0% | 81.5% | |
| Cytogenetics | |||||
| t(8;21) | 15.9% | 10.0% | 14.0% | 23.4% | .01 |
| inv(16) | 13.9% | 16.2% | 16.8% | 8.8% | .10 |
| Normal karyotype | 27.8% | 33.8% | 22.4% | 27.7% | .11 |
| t(9;11)(p22;q23)/11q23 | 17.6% | 15.4% | 17.5% | 19.7% | .65 |
| −5, −7, or +8 | 7.8% | 9.2% | 7.0% | 7.3% | .76 |
| Other | 17.1% | 15.4% | 22.4% | 13.1% | .10 |
| NPM1, mutant | 11.2% | 10.0% | 11.9% | 11.7% | .87 |
| CEBPα, mutant | 9.5% | 16.2% | 7.0% | 5.8% | .01 |
| FLT3-ITD, mutant | 22.4% | 20.8% | 19.6% | 27.0% | .28 |
| High allelic ratio FTL3-ITD (≥ 0.4), yes | 14.6% | 13.1% | 14.0% | 16.8% | .67 |
| Risk stratification, high‡ | 29.8% | 31.0% | 25.9% | 32.6% | .45 |
| CR | 84.9% | 86.2% | 82.5% | 86.1% | .62 |
Unknown values were not considered in P value calculations and are excluded from the results.
N = 45 patients have unknown race and are excluded from the results.
N = 18 patients have unknown ethnicity and are excluded from the results.
AAML1031 protocol risk group definition: low risk, inv(16)/t(16;16) or t(8;21), or NPM or CEBPα mutation; high risk, FLT3/ITD+ with high allelic ratio ≥0.4, or monosomy 5/del5q or 7, without low-risk features; and risk status unknown for 10 of 410.